AEON Biopharma
AEON
21 hedge funds and large institutions have $19.6M invested in AEON Biopharma in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 13 reducing their positions, and 70 closing their positions.
76% less funds holding
Funds holding: 86 → 21 (-65)
84.22% less ownership
Funds ownership: 91.21% → 6.99% (-84%)
85% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 13
92% less capital invested
Capital invested by funds: $253M → $19.6M (-$233M)
93% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 70
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SIM
Sandia Investment Management
Boston,
Massachusetts
|
+$1.31M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$546K |
| 3 |
Walleye Capital
New York
|
+$161K |
| 4 |
CCM
CAAS Capital Management
New York
|
+$119K |
| 5 |
FTUS
Flow Traders U.S.
New York
|
+$107K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$13.3M |
| 2 |
DKCM
Davidson Kempner Capital Management
New York
|
-$12.8M |
| 3 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
-$12.6M |
| 4 |
ECP
Empyrean Capital Partners
Los Angeles,
California
|
-$12.1M |
| 5 |
D.E. Shaw & Co
New York
|
-$11.9M |
AEON Hedge Fund Activity: Q1 2023 in Review
21 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q1 2023, worth a combined $19.6M — down 92% from $253M a quarter earlier.
Sellers outnumbered buyers: 70 funds closed out of AEON and 5 opened new positions — a net loss of 65 holders — while 13 trimmed existing stakes and 2 added.
The largest buyer was Sandia Investment Management, opening a new position worth an estimated $1.31M. The largest seller was Marshall Wace, exiting entirely with an estimated $13.3M sold.
- 21 institutional investors held AEON Biopharma (AEON) as of Q1 2023, down from 86 in Q4 2022.
- Funds reported $19.6M of AEON Biopharma stock for Q1 2023, down 92% quarter-over-quarter.
- 5 funds opened new AEON Biopharma positions in Q1 2023 and 70 closed out, a net change of -65 holders.
- The largest AEON Biopharma buyer in Q1 2023 was Sandia Investment Management, an estimated $1.31M added.
- The largest AEON Biopharma seller in Q1 2023 was Marshall Wace, an estimated $13.3M sold.
Based on aggregated 13F filings for Q1 2023.